Poor
Needs Revision
Patient Risk:
Moderate
Summary
Several statements about use, bleeding, interactions, contraindications (esp. pediatric/viral illness), and stopping before procedures are broadly consistent with the label excerpts, but multiple claims are unsupported or inaccurate for this specific product’s label content (e.g., “off-label use” framing and multiple interaction/precaution items not explicitly stated in the provided label text). Overall alignment is poor due to unsupported specifics.
Category Scores
Accurate Statements
Aspirin off-label use means using aspirin for a purpose not specifically approved on the drug’s label.
Not supported for this specific product; label excerpt does not address off-label definitions.
Aspirin should not be used for viral illnesses in children and teens due to the risk of Reye’s syndrome.
Contraindications 4.3: “Do not use aspirin in children or teenagers with viral infections because of the risk of Reye syndrome.”
Reye’s syndrome is a rare but serious condition associated with aspirin use in children and teens with viral illnesses.
Label excerpt 4.3 mentions risk of Reye syndrome but does not describe it as rare/serious.
Aspirin has known risks including bleeding risk.
Warnings/Precautions 5.1: “Aspirin and extended-release dipyridamole increases the risk of bleeding.”
Aspirin bleeding risks include gastrointestinal bleeding.
Warnings/Precautions 5.1: “GI side effects… and gross GI bleeding…”
Some statements about bleeding risk factors including other drugs that increase bleeding risk (e.g., anticoagulants, antiplatelet agents, chronic NSAIDs) align with the label.
Warnings/Precautions 5.1: lists examples including anticoagulants, antiplatelet agents, heparin, anagrelide, fibrinolytic therapy, and chronic NSAIDs.
Unsupported Statements
Aspirin off-label use can involve differences from the approved indication, dose, age group, or treatment population.
Not addressed by the provided label excerpts.
Aspirin is used to reduce the risk of blood clots in certain cardiovascular situations (approved uses).
The provided indication in the label is specifically to reduce risk of stroke in TIA/ischemic stroke due to thrombosis; “blood clots”/“certain cardiovascular situations” is broader than label wording.
Aspirin bleeding risks include, more rarely, intracranial bleeding.
Label excerpt provides an intracranial hemorrhage rate but does not characterize it as “more rarely.”
Aspirin has a gastritis and ulcer risk.
The excerpt mentions “Avoid using… in patients with a history of active peptic ulcer disease…” but does not state “gastritis” as a risk item.
Aspirin has drug interactions, including with other blood thinners.
Label excerpt does indicate increased bleeding risk with anticoagulants/antiplatelet agents, but the statement is generic and not tied to this product’s specific interaction description as written.
Aspirin can interact with some arthritis medicines like NSAIDs.
The label excerpt mentions chronic use of NSAIDs as a bleeding risk factor; it does not explicitly state “can interact” with arthritis medicines.
Some antidepressants can increase the bleeding risk when used with aspirin.
No antidepressant-specific interaction is present in the provided label excerpts.
Clinicians may screen for a history of ulcers or bleeding and other risk factors when considering off-label prevention with aspirin.
The label excerpt does not provide guidance about screening or “off-label prevention.”
People with a history of stomach ulcers or GI bleeding need extra caution or medical guidance before using aspirin.
The label excerpt says to avoid using in patients with active peptic ulcer disease, but does not provide the broader “extra caution or medical guidance” phrasing.
People with a prior hemorrhagic stroke need extra caution or medical guidance before using aspirin.
No prior hemorrhagic stroke-specific caution is included in the provided label excerpts.
People with uncontrolled bleeding disorders or very low platelets need extra caution or medical guidance before using aspirin.
No bleeding disorder/platelet-specific language is included in the provided label excerpts.
People with allergy or aspirin-triggered asthma need extra caution or medical guidance before using aspirin.
The label contains contraindications for aspirin allergy/NSAID allergy and asthma-related syndrome, but does not include the “extra caution or medical guidance” phrasing; also the statement is not limited to contraindication status.
Aspirin may need to be stopped in advance depending on the case and clinician plan before upcoming surgery or dental procedures.
No peri-procedural discontinuation guidance is present in the provided label excerpts.
Contradictions
Important Omissions
Specific dosage and administration for this product (e.g., “one capsule orally twice daily… swallow capsules whole… with or without food”) is not addressed at all in the listed statements.
Importance:
Moderate
This product’s key indication is to reduce risk of stroke in patients with TIA or completed ischemic stroke due to thrombosis; the response text includes a generic “blood clots” framing that omits this specificity.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-critical items are partially supported (Reye syndrome avoidance; bleeding risk and GI bleeding), but multiple specific precautions/interaction claims are not supported by the provided label excerpts, and some statements are broader than the label (e.g., peri-procedural stopping, antidepressants, prior hemorrhagic stroke, bleeding disorders/platelets).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Multiple statements are unsupported or too generic/broader than the provided label excerpts, including antidepressant bleeding interactions and peri-procedural discontinuation guidance, plus mismatch between “blood clots/cardiovascular situations” and the specific labeled stroke indication.
Suggested Improvement
Restrict claims to the provided label language: use the exact labeled indication (stroke risk reduction in TIA/completed ischemic stroke due to thrombosis), cite bleeding risk factors and examples as listed (anticoagulants/antiplatelets/heparin/anagrelide/fibrinolytics/chronic NSAIDs), and remove or rephrase unsupported statements not present in the excerpts (antidepressants, prior hemorrhagic stroke, bleeding disorders/platelets, peri-procedural stopping, gastritis wording). Include only label-supported administration/dosing if relevant.